Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
33 hedge funds and large institutions have $32.8M invested in Astria Therapeutics in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 7 closing their positions.
944% more call options, than puts
Call options by funds: $3.23M | Put options by funds: $310K
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
6% less funds holding
Funds holding: 35 → 33 (-2)
9.38% less ownership
Funds ownership: 56.22% → 46.84% (-9.4%)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
49% less capital invested
Capital invested by funds: $63.8M → $32.8M (-$30.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$329K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$296K |
| 3 |
Wolverine Trading
Chicago,
Illinois
|
+$84.4K |
| 4 |
BlackRock
New York
|
+$78.6K |
| 5 |
Millennium Management
New York
|
+$67.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$4.46M |
| 2 |
CC
Commodore Capital
New York
|
-$2.12M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$994K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$580K |
| 5 |
Renaissance Technologies
New York
|
-$493K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| $16K | -$33 | -5 | -0.2% |
|
27
Group One Trading
Chicago,
Illinois
| $12K | +$15.1K | +2,300 | New |
|
|
TRCT
28
Tower Research Capital (TRC)
New York
| $11K | +$12.9K | +1,958 | New |
|
|
BFEC
29
Benjamin F. Edwards & Company
St. Louis,
Missouri
| $2K | – | – | – |
|
30
Federated Hermes
Pittsburgh,
Pennsylvania
| $1K | +$171 | +26 | +68% |
|
|
CC
31
Commodore Capital
New York
| – | -$2.12M | -239,270 | Closed |
|
|
SCM
32
Soleus Capital Management
Greenwich,
Connecticut
| – | -$994K | -112,499 | Closed |
|
|
GCP
33
GSA Capital Partners
London,
United Kingdom
| – | -$221K | -24,996 | Closed |
|
34
T. Rowe Price Associates
Baltimore,
Maryland
| – | -$106K | -11,966 | Closed |
|
35
Goldman Sachs
New York
| – | -$99K | -11,221 | Closed |
|
|
CG
36
Cutler Group
San Francisco,
California
| – | -$1K | -116 | Closed |
|
37
Osaic Holdings
Scottsdale,
Arizona
| – | -$1K | -93 | Closed |
|
38
Wells Fargo
San Francisco,
California
| – | +$7 | +1 | +2% |
|
ATXS Hedge Fund Activity: Q4 2021 in Review
33 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q4 2021, worth a combined $32.8M — down 49% from $63.8M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ATXS and 5 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 9 added.
The largest buyer was Alyeska Investment Group, adding an estimated $329K. The largest seller was Perceptive Advisors, cutting an estimated $4.46M.
- 33 institutional investors held Astria Therapeutics (ATXS) as of Q4 2021, down from 35 in Q3 2021.
- Funds reported $32.8M of Astria Therapeutics stock for Q4 2021, down 49% quarter-over-quarter.
- 5 funds opened new Astria Therapeutics positions in Q4 2021 and 7 closed out, a net change of -2 holders.
- The largest Astria Therapeutics buyer in Q4 2021 was Alyeska Investment Group, an estimated $329K added.
- The largest Astria Therapeutics seller in Q4 2021 was Perceptive Advisors, an estimated $4.46M sold.
Based on aggregated 13F filings for Q4 2021.